Cancer feature: cnaSKCM3

ACSF3 ADAD2 ANKRD11 APRT ATMIN ATP2C2 BANP BCMO1 C16orf46 C16orf74 C16orf95 CA5A CBFA2T3 CDH13 CDH15 CDT1 CDYL2 CENPN CMC2 CMIP COTL1 COX4I1 CRISPLD2 CTC-786C10.1 CTU2 CYBA DNAAF1 DYNLRB2 EMC8 FBXO31 FOXC2 FOXF1 FOXL1 GALNS GAN GCSH GINS2 GSE1 HSBP1 HSD17B2 HSDL1 IL17C IRF8 JPH3 KCNG4 KIAA0513 KLHDC4 KLHL36 MAF MAP1LC3B MBTPS1 MLYCD MPHOSPH6 MTHFSD MVD NECAB2 OSGIN1 PABPN1L PIEZO1 PLCG2 RNF166 RP11-178L8.4 RP11-505K9.4 RP11-680G10.1 RP11-830F9.6 SDR42E1 SLC22A31 SLC38A8 SLC7A5 SNAI3 TAF1C TLDC1 TRAPPC2L USP10 WFDC1 WWOX ZC3H18 ZCCHC14 ZDHHC7 ZFPM1 ZNF469 ZNF778

Known Driver Genes: None

Copy number alternation: loss

GSK626616AC

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer